AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 SEP 6 - (NewsRx Network) -- by Michael Greer, senior medical writer - Potent antiretroviral therapy has benefited some demographic groups of HIV patients more than others, researchers in Maryland report.
"The advent of highly active antiretroviral therapy (HAART) has reduced the incidence of most ADS-related opportunistic illnesses (OI) and death in HIV infected individuals," according to Richard D. Moore and colleagues at Johns Hopkins University, Baltimore.
However, although women and injecting drug users have shared in the benefits of HAART, Moore and coworkers found that they have seen less pronounced reductions in risk compared with other patient demographic groups.
Female HIV patients have seen marked improvements in the amount of time they can expect to have before dying or developing an AIDS-defining illness since the introduction of HAART in 1995, study data showed. The median disease-free survival time increased by 14% for female patients with relatively good immune status and by 34% for patients with badly impaired immune systems. Male patients, however, saw 43% and 100% improvements respectively over the same period of time.
Similarly, patients who used injection drugs saw increased disease-free survival times of 16% and 34% in the HAART era, compared with improvements of 65% and 135% for nonusers, Moore and team reported. Women and injecting drug users had some 1.3 times higher ADS progression risks than did ...
Source: HighBeam Research, Some Groups Have Benefited Less From Antiretroviral Therapy.(Brief...